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Corpora amylacea (CA) in the human brain are polyglucosan bodies that accumulate
residual substances originated from aging and both neurodegenerative and infectious
processes. These structures, which act as waste containers, are released from the brain
to the cerebrospinal fluid, reach the cervical lymph nodes via the meningeal lymphatic
system and may be phagocytosed by macrophages. Recent studies indicate that CA
present certain neoepitopes (NEs) that can be recognized by natural antibodies of the IgM
class, and although evidence of different kinds suggests that these NEs may be formed by
carbohydrate structures, their precise nature is unknown. Here, we adapted standard
techniques to examine this question. We observed that the preadsorption of IgMs with
specific carbohydrates has inhibitory effects on the interaction between IgMs and CA, and
found that the digestion of CA proteins had no effect on this interaction. These findings
point to the carbohydrate nature of the NEs located in CA. Moreover, the present study
indicates that, in vitro, the binding between certain natural IgMs and certain epitopes may
be disrupted by certain monosaccharides. We wonder, therefore, whether these
inhibitions may also occur in vivo. Further studies should now be carried out to assess
the possible in vivo effect of glycemia on the reactivity of natural IgMs and, by extension, on
natural immunity.
Keywords: neoantigen, neoepitope, immunoglobulin M, natural antibodies, corpora amylacea, brain aging,
hyperglycemia, diabetesINTRODUCTION
Corpora amylacea (CA) in the human brain are polyglucosan aggregates that were first described
by J.E. Purkinje in 1837 (1). They are intracellular astrocytic bodies that accumulate mainly in the
periventricular and subpial regions of the aged brain (2–4), but are also present in large numbers
in specific areas of the brain in neurodegenerative conditions (5–8). Different studies postulate
that the function of CA is to entrap residual products derived from aging or degenerative
processes (2, 4, 9–12). Accordingly, while essentially constituted of polymerized hexoses (2, 3),org June 2021 | Volume 12 | Article 6181931
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components have been attributed to CA. These products are
mainly derived from neurons, astrocytes, oligodendrocytes or
the blood (8, 12–17), or even related to viral, fungal or
microbial infections (18–20). However, the presence of some
of these components remain controversial (10, 21). In 2017, we
reported that some positive immunostainings described in CA
may have been induced by contaminant immunoglobulins M
(IgMs) present in commercial antibodies, giving rise to false
positive results (10). Later, in 2018, we reviewed and ruled out
some of the components that have been reported to occur in
CA. We observed that CA contain glycogen synthase (GS),
which is presumed to take part in the formation of the
polyglucosan structure, as well as ubiquitin and p62 proteins,
which are both involved in the processing of waste products
(21). Recently, an immunofluorescence study, which excluded
the possible false positive staining caused by IgMs, reported
that CA contain tau protein (22). The possible role of CA in
trapping residual products is also supported by electron
microscopy studies, which have described some cell debris
inside the CA, including impaired mitochondria and
lysosome-like vesicles, originating from degenerative
processes (9, 12, 23). Moreover, we recently revealed that CA
are released from the brain into the cerebrospinal fluid (CSF),
reaching the cervical lymph nodes via the meningeal lymphatic
system, and we observed that CA can be phagocytosed by
macrophages in vitro. All these findings indicate that CA can
act as containers that remove waste products from the
brain (24).
CA share some features with a type of polyglucosan bodies,
referred to as PAS granules, which appear in the mouse brain.
Both, PAS granules and CA, are round or oval shaped and have a
high polysaccharide content, and therefore become positively
stained with periodic acid-Schiff (PAS). Both structures are age-
related deposits that entrap residual products and present some
neoantigens, or more specifically neoepitopes (NEs), which can be
recognized by natural antibodies of the IgM isotype (9, 10, 21, 24–
30). NEs are epitopes that originate de novo in physiological
conditions and also in pathological situations such as ischemia,
diabetes, atherosclerosis, cancer and inflammatory events, as well
as in aging (31–35). For its part, natural antibodies are generated
throughout a lifetime, even during fetal development and before
external antigen exposure (36–39). Their repertoire and reactivity
pattern have been determined throughout evolution and are
remarkably stable within species and even between species (40,
41), explaining their presence as contaminants in a wide range of
commercial antibodies. They constitute a first line of immune
defense, but also have important functions in the physiology of the
organism (42). Some of these natural antibodies are able to
recognize the NEs that occur in, for example, cell remnants and
senescent or apoptotic cells, taking part in their controlled
elimination and, thus, contributing to the maintenance of tissue
homeostasis (31, 37, 38, 41–45). Therefore, the presence of NEs in
both CA and PAS granules and the existence of natural IgMs that
target them reinforce the idea that CA and PAS granules are
involved in brain cleaning or in protective processes.Frontiers in Immunology | www.frontiersin.org 2The nature of the NEs present in CA and recognized by
natural IgMs remains unknown but several observations suggest
that they can be of a carbohydrate nature. For instance, the NEs
contained in PAS granules of the mouse brain, recognized by
natural IgMs, have a carbohydrate nature (27, 30). In addition,
natural IgM antibodies have been described to recognize some
carbohydrates, such as advanced glycation end products, whose
production is increased with aging (37, 44–48). In fact, many a-
glycan antibodies present in human sera belong to the IgM class
and are natural antibodies (49). In any case, IgMs often recognize
epitopes that act as markers of own residual structures (42) and,
as mentioned previously, CA contain some of these residual
structures. Therefore, it seemed appropriate to explore whether
the NEs of CA do have a carbohydrate nature. However, it has to
be taken into account that in living beings glycans show great
complexity, greater than that of proteins, nucleic acids and lipids,
and currently there are few or at least insufficient tools to study
glycans with the same ease and precision as that associated with
the study of proteins (50). Thus, in this first attempt we adapted
standard techniques to determine the nature of NEs of CA.
Two different approaches were used. First, IgM preadsorptions
with increasing concentrations of specific carbohydrates were
performed to ascertain if the preadsorption produced a partial or
total inhibition of CA staining with the IgMs. As a control, the same
preadsorption studies were undertaken by staining the CA with
concanavalin A (ConA). ConA staining of CA has been previously
described in the literature (24, 51). ConA is a plant lectin that binds to
hexoses in which the d-pyranose ring system presents hydroxyl
groups at C-3 and C-4 in the equatorial plane, as well as a hydroxyl
group at C-6. These types of hexoses include d-mannose (Man) and
d-glucose (Glc), but not d-galactose (Gal), in which the hydroxyl
group at C-4 is in the axial plane. ConA also binds to certain sugars
with a five-membered furanoid ring form, such as ketohexose d-
fructose, in which the hydroxyl groups at C-3, C4 and C-6 are
oriented similarly to those in the mannopyranosyl ring, and
aldopentose d-arabinose, in which the hydroxyl groups at C-2, C-3
and C-5 show a similar orientation (52–54). Thus, if carbohydrate
preadsorption works well, CA staining with fluorochrome-labeled
ConAwill be blocked by Glc, Man, d-fructose (Fru) and N-acetyl-d-
glucosamine (GlcNAc), but not by Gal or N-acetyl-d-galactosamine
(GalNAc). Another control of the preadsorption with sugars was
based on the staining of CA with an a-p62 antibody. As p62 is a
protein, the preadsorption of the a-p62 antibody with the different
sugars should not interfere with the staining of CA. This control was
used to demonstrate that the preadsorption with the sugars did not
block the antibodies directed against the proteins in the CA.
The second approach to study the interaction of the IgMs
with CA involved staining the CA after digestion with the
peptidic enzyme pepsin. If IgM recognizes glycosides that are
not linked to proteins, the staining should be maintained after
the digestion. As control experiments, AF555 NHS ester probe,
a-p62 antibody and fluorescein-labeled ConA were used to stain
CA. The AF555 NHS ester probe labels primary amines (R-NH2)
of proteins, amine-modified oligonucleotides, and other amine-
containing molecules. On the one hand, since AF555 NHS ester
probe and a-p62 bind to proteins, pepsin digestion mightJune 2021 | Volume 12 | Article 618193
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staining with ConA should not be affected since ConA binds to
carbohydrate structures.MATERIAL AND METHODS
Preadsorption Studies
Human Brain Samples
Post-mortem brain samples were obtained from the Banc de Teixits
Neurològics (Biobanc-Hospital Clıńic-IDIBAPS, Barcelona). Frozen
hippocampal sections (6 µm-thick; stored at -80°C) were obtained
from three cases of neuropathologically confirmed Alzheimer’s
disease, two cases of subcortical vascular encephalopathy and one
case of Lewy body dementia. Medical data of these cases are detailed
in Table S1 (Supplementary Material). All procedures involving
human samples were performed in accordance with appropriate
guidelines and regulations. All experiments involving human tissue
were approved by the Bioethical Committee of the Universitat
de Barcelona.
Immunofluorescence and ConA Staining
Frozen hippocampal sections were air dried for 10 min and then
fixed with acetone for 10 min at 4°C. After 2 h of drying, sections
were rehydrated in phosphate-buffered saline (PBS) and then
blocked and permeabilized with 1% bovine serum albumin in
PBS (Sigma-Aldrich) (blocking buffer, BB) with 0.1% Triton
X-100 (Sigma-Aldrich) for 20 min. They were then washed with
PBS and incubated with the primary antibody overnight at 4°C.
The slides were then washed and incubated for 1 h at room
temperature with the secondary antibody. Nuclear staining was
performed with Hoechst (2 mg/mL, H-33258, Fluka, Madrid,
Spain) and the slides were washed and coverslipped with
Fluoromount (Electron Microscopy Sciences, Hatfeld, PA,
USA). Staining controls were performed by incubating with BB
instead of the primary antibody before incubation with the
secondary antibody.
The following were used as primary antibodies: mouse
monoclonal IgG2a against p62 (diluted 1:200; Abcam, ab56416),
human IgMs purified frommyeloma serum (MS-IgMs) (1:10; AbD
Serotec, OBT1524) and human IgMs purified from normal serum
(NS-IgMs) (1:25; Sigma, I8260). Previous studies indicated that
both pools of IgMs contain IgMs that bind to CA. The following
were used as the secondary antibodies:AlexaFluor (AF) 488 goata-
mouse IgG2a (1:250; Life Technologies, A-21131) and AF488 goat
a-human IgM (heavy chain) (1:200; Life Technologies, A-21215).
In some of the experiments, samples were incubated overnight
with fluorescein-labeled ConA (1:250; Vector Laboratories)
instead of the primary antibody and, as incubation with the
secondary antibody was not needed, the slides were immediately
washed and coverslipped with Fluoromount.
Preadsorption With Carbohydrates
Primary antibodies and ConAwere preadsorbed in different assays
with the monosaccharides Glc (Scharlab, GL01271000), Man
(Sigma Aldrich, M2D69), Fru (Sigma Aldrich, F0127), GalFrontiers in Immunology | www.frontiersin.org 3(Sigma Aldrich, G0750), GlcNAc (Sigma Aldrich, A8625) and
GalNAc (Sigma Aldrich, A2795). For each monosaccharide, we
first prepared sugar dilutions of 0 (control), 50, 100, 200 and 400
mM in PBS, as well as 800 mM in some of the indicated cases. The
preadsorption was then performed by using these sugar solutions
to dilute the primary antibodies or ConA at the indicated
concentrations, and the mixtures were maintained overnight at
4°C with agitation. The different hippocampal sections were
incubated with each mixture instead of the primary antibody.
Some preadsorption series of different sugars were performed at
the same time and the 0 mM tissue section was shared. Thus, these
series show the same fluorescence values and images at 0 mM. To
reduce variability, consecutive hippocampal sections were used in
each assay, i.e., in the study of the preadsorption of an antibody (or
ConA) with a determinate sugar.
Image Acquisition
Images were captured with a fluorescence laser and optical
microscope (BX41, Olympus, Germany) and saved in tiff
format. All the images for each combination of antibody (or
ConA) and sugar were taken using the same microscope, laser
and software settings. The time of capture was adapted to each
staining, but the control or reference images were acquired with
the same time of capture as that of the respective set of images.
Image Processing and Fluorescence
Intensity Measurements
Themerging of the images from the different fluorescence channels
was performed using the FIJI program (National Institutes of
Health, USA). Image analysis and quantifications were also
performed with the FIJI program, not using the composite image,
but the original image in the appropriate color. All CA of each
hippocampal section were analyzed. The degree of staining of each
CAwas quantified as described below. For eachCA,wefirst defined
the region of interest (ROI) manually by tracing the outline of the
CA using the elliptical selection tool of the FIJI program. We then
obtained themeangray value of theROI,which corresponded to the
mean fluorescence intensity (in arbitrary units) of the outlined CA.
To minimize possible differences in the basal intensity of each
image, for eachCA,wemoved theROI toanareanext to theCAand
obtained the mean fluorescence intensity of the background.
Thereafter, we obtained the relative intensity (RI) for each CA,
which was defined as the difference between the mean fluorescence
intensity of the CA and the mean fluorescence intensity of the
respective background. To standardize the data obtained from the
different preadsorption studies, for each combination of antibody
and sugar, we defined the mean value of all the RIs obtained with 0
mM of the monosaccharide as the reference value (RV). The
intensity of each CA was expressed as a percentage with respect
to the reference value (RI%), i.e., 100*RI/RV. It should benoted that
in all the cases, the mean RI% value will be 100% for 0 mM. If the
carbohydrate preadsorption interferes with the CA staining, this
percentage will decrease with increasing carbohydrate
concentrations. The original data of the fluorescence intensities of
the CA and their corresponding backgrounds are included in the
Supplementary Materials.June 2021 | Volume 12 | Article 618193
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Statistical analysis was performed with the ANOVAmodule of SPSS
Statistics (IBM). For each study, to determine if the sugar
concentration influences the RI%, the variable sugar concentration
has been defined as the independent variable and the RI% variable as
the dependent one. When the ANOVA indicates that the variable
sugar concentration influences the RI%, the Scheffe test was used for
post hoc comparisons in order to compare the values obtained at each
sugar concentration to the values obtained at 0mM.Differenceswere
considered significant when p < 0.01.However, as commented in the
Editorial ofNaturedated20thMarch2019 (55),usingonlypvalues to
determine significance can also lead to some analyses being biased,
some false positives being overhyped and some genuine effects being
overlooked. Logic, background knowledge and experimental design
shouldbe consideredalongsidepvalues and similarmetrics to reacha
conclusion and decide on its certainty. Accordingly, in the present
study, p values were used alongside other findings to reach
conclusions based on a general view.
Digestion Studies
Human CSF Samples Used to Obtain CA
Post-mortem ventricular CSF samples were obtained from
three cases of neuropathologically affected patients and one non-
neuropathologically affected patient. When extracted, the CSF
samples were centrifuged at 4,000 g at 4°C for 10 min and the
pellets obtained were stored at -80°C until use. All these procedures
were performed at the Banc de Teixits Neurològics (Biobanc-
Hospital Clıńic-IDIBAPS, Barcelona). Medical data about these
cases are detailed in Table S2 (Supplementary Material).
CA Extraction and Pepsin Digestion
CSF pellets were re-suspended in PBS and filtered through a
35-µm porous filter (Fisher Scientific, 12934257). The samples
were then centrifuged at 700 g for 10 min. The supernatants were
then rejected and pellets were re-suspended in PBS to obtain 500-
µL aliquots. Another centrifugation at 700 g for 10 min was
performed, and the pellet was re-suspended in 500 mL of a solution
of 4 mg/mL of pepsin (Merck, P6887) in 10 mM HCl (pH 2).The
suspension was maintained under agitation overnight at 37°C.
Control experiments were performed by incubating the samples
overnight with PBS instead of the pepsin solution.
Immunofluorescence, AF555 NHS Ester Staining,
and ConA Staining
After pepsin digestion, samples were washed 3 times by
centrifugation at 700 g for 10 min and the pellet was re-
suspended in 1,000 mL of PBS. The samples were then incubated
with the primary antibody overnight at 4°C. Thereafter, samples
were washed 3 times by centrifugation and incubated for 1 h at
room temperature with the secondary antibody. Samples were
then washed twice and centrifuged again at 700 g for 10 min to
obtain pellets that were then re-suspended in 40 mL of PBS. These
40-mL samples were spread on to slides, air dried and coverslipped
with Fluoromount. Staining controls were performed by
incubating with PBS instead of the primary antibody.
The following were used as the primary antibodies: mouse
monoclonal IgG2a against p62 (diluted 1:200; Abcam, ab56416)Frontiers in Immunology | www.frontiersin.org 4and NS-IgMs (1:25; Sigma, I8260). The following were used as
the secondary antibodies: AF555 goat a-mouse IgG2a (1:250; Life
Technologies, A-21131) and AF488 goat a-human IgM (heavy
chain) (1:200; Life Technologies, A-21215).
In some of the immunofluorescence experiments, samples
were incubated with fluorescein-labeled ConA (1:250; Vector
Laboratories, FL-1001-25) overnight or with AF555 NHS ester
probe (1 mg/mL; ThermoFisher Scientific, A37571) 1h at room
temperature with agitation, instead of the primary antibodies.
In some cases, sequential double staining was performed with
the a-p62 antibody and ConA and with the a-p62 antibody and
NS-IgMs. The a-p62 antibody and ConA double staining was
carried out in the same way as the simple immunofluorescence
procedure, but adding an overnight incubation at 4°C with ConA
after the incubation with the secondary antibody. Regarding the
a-p62 antibody and NS-IgM double immunostaining, the
samples were incubated with the a-p62 antibody overnight at
4°C first and then with NS-IgMs overnight at 4°C, before being
incubated with the secondary antibodies simultaneously for 1 h
at room temperature.
Image Acquisition and Processing
Image acquisition and processing were performed as described
above for the sugar preadsorption studies.RESULTS
Sugar Preadsorption Studies
Effects of Sugar Preadsorption on ConA Staining of CA
As mentioned before, it is well established that ConA binds to
CA and that fluorochrome-labeled ConA can be used to stain CA
(24, 51). Thus, we performed the preadsorption studies with the
different sugars using fluorochrome-labeled ConA. As shown in
the upper row of Figure 1, preadsorption with glucose interfered
with the staining. While ConA staining of the CA can be clearly
observed when the Glc concentration is 0 mM (i.e., positive
control), the staining is practically absent in the presence of
glucose at all the tested concentrations. The same pattern was
observed when the preadsorption was performed with Man, Fru
or GlcNAc. However, when the preadsorption was performed
with Gal or GalNAc, the staining with ConA was maintained,
even at the highest concentration of sugar.
Table 1 presents the mean RI% values for each carbohydrate
experiment and each carbohydrate concentration. This table
contains the summary of all the results of the section to allow
and facilitate the comparison between them. As can be observed,
in the case of ConA staining, statistical analysis of the data from
the Glc experiments indicated that the RI% decreased with the
preadsorption, being significantly lower than 100% for all the
tested concentrations (p < 0.01), i.e., lower than that of the
reference value at 0 mM. This indicates that Glc significantly
interfered with the ConA staining of CA. For Man, Fru and
GlcNAc, there was also a significant decrease in the staining with
increasing sugar concentrations. This was not the case for Gal
and GalNAc, which did not reduce the staining. There were no
significant differences with respect to their controls, except forJune 2021 | Volume 12 | Article 618193
Riba et al. Neoepitopes in Brain Corpora AmylaceaFIGURE 1 | Representative images of hippocampal sections stained with ConA (green) and Hoechst (blue). Each row corresponds to a preadsorption study
performed with the indicated carbohydrate. Sugar concentrations are indicated above. The staining of CA (green) disappeared or decreased when the preadsorption
was performed with Glc, Man, Fru or GlcNAc, but was not affected by Gal or GalNAc. Some discrepancies in the basal staining can be appreciated between the
different preadsorption experiments (see, for example, the first column corresponding to the positive controls); for the statistical analysis, these discrepancies have
been corrected in basis of the background intensity, as indicated in the Methods section. Scale bar: 100 mm.Frontiers in Immunology | www.frontiersin.org June 2021 | Volume 12 | Article 6181935
Riba et al. Neoepitopes in Brain Corpora AmylaceaGalNAc at 800 mM, which resulted in a mean RI% of 168.49 that
was higher than the value at 0 mM. This was considered an
outlier because of the absence of any clear trend at the other
concentrations (see below). In any case, GalNAc did not decrease
the staining when used to preadsorb ConA.
Figure 7A presents a graphical view of these data, showing
the different dynamics for Gal and GalNAc with respect to the
other sugars. These results were expected according to the
carbohydrate-binding domain of ConA, indicating that sugar
preadsorption could be an optimal method for studying the
nature of the interaction. This figure contains the summary of all
the results of the section, and is located at the end of the section.
Effects of Sugar Preadsorption on a-p62
Staining of CA
Before using the preadsorption with sugars to study the interaction
between IgMs and CA, we applied the preadsorption method to
analyze the interaction between the a-p62 antibody and CA. As the
a-p62 antibody stains the protein p62, it was expected that
preadsorption with the different sugars would not interfere withFrontiers in Immunology | www.frontiersin.org 6this immunostaining and, thus, a-p62 antibody staining would be
usedasanegative control tovalidate the sugarpreadsorptionmethod.
Figure 2 shows representative images of CA stained with the
a-p62 antibody, previously preadsorbed with Glc, Man, Fru, Gal,
GlcNAc and GalNAc at different concentrations ranging from 0
mM to 800 mM. As can be observed, the staining was maintained
at all the sugar concentrations tested, indicating that the presence
of the different sugars did not affect the a-p62 antibody staining.
Table 1 presents the mean RI% values obtained from the
different p62 assays. The values ranged from 53.63% to 127%,
with no significant differences compared to the values obtained
at 0 mM (p < 0.01 in all cases). Moreover, the graphical view of
these data (Figure 7B) shows no downward trends in relation to
the sugar concentration for any of the four sugars tested.
Effects of Sugar Preadsorption on IgMs
Staining of CA
As the preadsorption method used was reliable in describing the
sugar-based interaction between ConA and CA and given that
the staining of CA with antibodies directed against proteins wasTABLE 1 | Fluorescence intensity of CA staining expressed as mean RI% (± s.e.m.; N).
0 mM 50 mM 100 mM 200 mM 400 mM 800 mM
ConA Glc 100,00 ( ± 2,94; 20) 0,11 ( ± 0,11; 24)* 0,00 ( ± 0; 14)* 0,04 ( ± 0,04; 16)* 0,00 ( ± 0; 19)* —
Fru 100,00 ( ± 6,02; 7) 0,00 ( ± 0; 5)* 0,00 ( ± 0; 5)* 0,00 ( ± 0; 6)* 0,00 ( ± 0; 10)* —
Man 100,00 ( ± 2,94; 20) 0,01 ( ± 0,01; 29)* 0,00 ( ± 0; 17)* 0,00 ( ± 0; 13)* 0,00 ( ± 0; 20)* —
GlcNAc 100,00 ( ± 5,14; 8) 0,00 ( ± 0; 9)* 0,00 ( ± 0; 10)* 0,00 ( ± 0; 7)* 0,00 ( ± 0; 8)* —
Gal 100,00 ( ± 5,02; 20) 113,84 ( ± 7,5; 33) 114,29 ( ± 15,18; 12) 124,53 ( ± 12,1; 10) 85,61 ( ± 5,37; 18) —
GalNAc 100,00 ( ± 5,29; 19) 95,68 ( ± 7,8; 15) 135,36 ( ± 7,19; 33) 98,31 ( ± 10,56; 12) 168,49 ( ± 5,87; 57)** —
p62 Glc 100,00 ( ± 5,43; 54) 112,71 ( ± 6,86; 57) 106,29 ( ± 6,04; 48) 110,03 ( ± 6,33; 49) 113,09 ( ± 8,77; 46) 110,43 ( ± 7,79; 47)
Fru 100,00 ( ± 6,99; 64) 97,17 ( ± 7,76; 59) 83,91 ( ± 5,24; 56) 110,83 ( ± 7,33; 77) 90,7 ( ± 6,06; 54) 73,80 ( ± 5,10; 63)
Man 100,00 ( ± 6,99; 64) 88,48 ( ± 6,62; 56) 108,27 ( ± 10,24; 36) 74,06 ( ± 5,47; 57) 92,53 ( ± 7,03; 68) 80,05 (6,76; 43)
GlcNAc 100,00 ( ± 25; 12) 114,79 ( ± 34,35; 11) 54,88 ( ± 9,95; 16) 73,42 ( ± 14,22; 24) 126,59 ( ± 21,72; 14) 69,38 ( ± 10,03; 32)
Gal 100,00 ( ± 8,06; 61) 65,22 ( ± 5,88; 32) 117,3 ( ± 7,51; 55) 123,98 ( ± 8,55; 55) 53,63 ( ± 11,47; 14) 80,99 ( ± 9,53; 34)
GalNAc 100,00 ( ± 25; 12) 61,71 ( ± 5,46; 31) 81,42 ( ± 28,07; 11) 80,39 ( ± 17,28; 13) 57,94 ( ± 7,51; 24) 64,16 ( ± 9,74; 12)
MS-IgM (S1) Glc 100,00 ( ± 7,66; 29) 80,28 ( ± 7,65; 20) 46,97 ( ± 3,64; 34)* 14,39 ( ± 1,68; 21)* 0,33 ( ± 0,23; 9)* —
Fru 100,00 ( ± 8,9; 19) 78,02 ( ± 15,23; 7) 69,59 ( ± 5,67; 6) 37,15 ( ± 5,17; 5)* 5,15 ( ± 1,21; 7)* —
Man 100,00 ( ± 7,66; 29) 69,57 ( ± 6,04; 30)* 27,45 ( ± 3,18; 14)* 25,32 ( ± 3,04; 13)* 0,65 ( ± 0,2; 7)* —
Gal 100,00 ( ± 8,9; 19) 66,21 ( ± 4,92; 8) 44,15 ( ± 2,9; 12)* 0,6 ( ± 0,47; 13)* 0,78 ( ± 0,36; 13)* —
MS-IgM (S2) Glc 100,00 ( ± 4,54; 26) 91,14 ( ± 4,81; 11) 41,77 ( ± 4,01; 9)* 35,61 ( ± 9,67; 2)* 4,3 ( ± 2,45; 10)* —
Fru 100,00 ( ± 3,14; 79) 48,69 ( ± 5,13; 27)* 37,08 ( ± 3,81; 34)* 28,51 ( ± 2,38; 31)* 0,41 ( ± 0,21; 28)* —
Man 100,00 ( ± 8,42; 39) 95,45 ( ± 6,98; 34) 90,21 ( ± 9,23; 15) 31,73 ( ± 8,21; 16)* 4,17 ( ± 1,36; 10)* —
Gal 100,00 ( ± 3,55; 66) 59,79 ( ± 3,24; 43)* 43,12 ( ± 2,15; 33)* 7,7 ( ± 0,7; 24)* 0,19 ( ± 0,12; 7)* —
NS-IgM (S1) Glc 100,00 ( ± 8,14; 53) 0,26 ( ± 0,26; 18)* 0,00 ( ± 0; 36)* 0,00 ( ± 0; 36)* 0,00 ( ± 0; 32)* —
Fru 100,00 ( ± 9,31; 9) 84,46 ( ± 7,61; 37) 65,51 ( ± 9,14; 11) 43,83 ( ± 2,39; 60)* 35,72 ( ± 4,95; 20)* —
Man 100,00 ( ± 9,31; 9) 63,4 ( ± 2,78; 21)* 57,41 ( ± 3,44; 43)* 44,69 ( ± 2,96; 17)* 42,07 ( ± 2,93; 22)* —
GlcNAc 100,00 ( ± 8,14; 53) 50,43 ( ± 6,85; 37)* 53,23 ( ± 6,97; 40)* 45,88 ( ± 7,42; 35)* 32,62 ( ± 4,86; 39)* —
Gal 100,00 ( ± 6,04; 36) 108,54 ( ± 5,23; 30) 134,42 ( ± 8,75; 16)* 61,68 ( ± 3,46; 9)* 93,08 ( ± 7,95; 15) —
GalNAc 100,00 ( ± 6,04; 36) 91,01 ( ± 5,12; 24) 87,39 ( ± 5,05; 13) 120,64 ( ± 12,25; 15) 80,13 ( ± 3,41; 29) —
NS-IgM (S2) Glc 100,00 ( ± 4,6; 67) — — 26,16 ( ± 5,28; 31)* 0,52 ( ± 0,28; 30)* 0,00 ( ± 0; 31)*
Fru 100,00 ( ± 4,87; 42) — — 63,71 ( ± 4,89; 30)* 62,85 ( ± 3,29; 29)* 19,28 ( ± 4,25; 23)*
Man 100,00 ( ± 5,57; 44) — — 91,43 ( ± 3,76; 46) 46,98 ( ± 3,79; 36)* 13,63 ( ± 1,42; 58)*
GlcNAc 100,00 ( ± 4,6; 67) — — 61,76 ( ± 4,89; 25)* 48,41 ( ± 2,47; 25)* 28,41 ( ± 4,9; 18)*
Gal 100,00 ( ± 4,59; 86) — — 85,13 ( ± 3,71; 64) 84,09 ( ± 3,07; 52) 58,62 ( ± 2,78; 56)*
GalNAc 100,00 ( ± 4,59; 86) — — 92,33 ( ± 4,94; 77) 86,33 ( ± 5,03; 55) 68,45 ( ± 4,8; 58)*June 2021 | VolumTable 1. Mean values of CA fluorescence when stained with ConA, a-p62, MS-IgM and NS-IgM and previously preadsorbed with the indicated sugars at the indicated concentrations. For
each sugar assay, the values are expressed as RI%, i.e. percentage respect to the mean value of fluorescence obtained in 0 mM, ( ± s.e.m.; N). * indicates significant differences respect to
0 mM (p < 0,01). ** indicates a significant value considered outlier (see text).— indicates not tested. S1 and S2 indicate different series. Note that in the case of ConA, all sugars produce a
decrease of the CA staining, except Gal and GalNAc. For a-p62, none of the tested sugars interfere with the staining, indicating that the staining of this protein is not affected by the sugar
preadsorption. Contrarily, all tested sugars interfere with the staining with the MS-IgM, reaching the mean RI% values near to 0% at 400 mM. In the case of NS-IgM, Glc is the sugar that
produces the highest decrease, while Gal and GalNAc only produce a significant decrease at 800 mM, producing a lower than 42% reduction in RI%.
Bold values are the significant ones, to improve visualization.e 12 | Article 618193
Riba et al. Neoepitopes in Brain Corpora Amylaceanot affected by the sugar preadsorption, we applied the
preadsorption method to analyze if sugars interfered with the
interaction between IgMs and CA. We used two different sources
of IgMs: those obtained from myeloma serum (MS-IgMs) and
those obtained from normal human serum (NS-IgMs).
In the case of MS-IgMs, we tested the preadsorption of IgMs
with Glc, Gal, Fru and Man at concentrations ranging from 0Frontiers in Immunology | www.frontiersin.org 7mM to 400 mM. As it was necessary to replicate the assay with
the NS-IgMs (see below), the experiment with MS-IgMs was also
replicated in order to analyze the robustness of the results. Thus,
the preadsorption of MS-IgMs included two series, S1 and S2.
Figures 3 and 4 show representative images of the staining of
CA with MS-IgMs for each sugar at each concentration,
corresponding to S1 and S2, respectively. In the absence ofFIGURE 2 | Representative images of hippocampal sections stained with the a-p62 antibody (green) and Hoechst (blue). Each row corresponds to a preadsorption
study performed with the indicated carbohydrate. Sugar concentrations are indicated above. The staining of CA (green) is always present for all the sugars tested
and at all the sugar concentrations. Scale bar: 100 mm.June 2021 | Volume 12 | Article 618193
Riba et al. Neoepitopes in Brain Corpora Amylaceasugars, i.e. the positive controls of the staining, the staining of CA
can be appreciated. When increasing the sugar concentration,
the staining becomes weaker or even disappears.
Table 1 shows the mean RI% values for each experimental
condition, including the results from S1 and S2. Statistical
significances with respect to the values obtained at 0 mM are
indicated. As can be observed, all the sugars interfered with the
staining, with the sugar concentrations of 200 mM and 400 mM
producing a significant decrease. Moreover, as can be observed in
the graphical view of these data (Figures 7C, D corresponding to
S1 and S2, respectively), there was a gradual decrease in staining
when the sugar concentration increased. Although there were
some discrepancies when comparing S1 and S2 (see, for example,
Man at 50 and 100 mM), the general trends observed in S1 wereFrontiers in Immunology | www.frontiersin.org 8the same as those observed in S2. Furthermore, the downward
trends were similar for the different sugars, with the RI% values
at 400 mM close to 0%. Thus, the results obtained with MS-IgMs
indicated that the interaction between the MS-IgMs and CA was
affected by all the sugars tested.
In the case of NS-IgMs, we first tested the preadsorption with
Glc, Gal, Fru, Man, GlcNAc and GalNAc at concentrations
ranging from 0 mM to 400 mM (S1). After considering the
need to include the concentration of 800 mM, we performed a
second series (S2) with all the sugars at concentrations of 0, 200,
400 and 800 mM. Representative images corresponding to S1
and S2 can be found in Figures 5 and 6.
Table 1 presents the mean RI% values from S1 and S2 and the
statistical significances with respect to the values obtained atFIGURE 3 | Representative images of hippocampal sections stained with MS-IgMs and Hoechst (blue) obtained in the first series (S1). Each row corresponds to a
preadsorption study performed with the indicated carbohydrate. Sugar concentrations are indicated above. Note that the staining of CA becomes weaker with
increasing sugar concentrations and even disappears. Scale bar: 100 mm.June 2021 | Volume 12 | Article 618193
Riba et al. Neoepitopes in Brain Corpora Amylacea0 mM. The graphical view of these data is presented in
Figures 7E, F. As can be observed, the results from S1 and S2
were very similar. The different sugars seem to interfere in
different ways with the staining of CA with NS-IgM. Glc had
the largest effect on the staining, with the RI% close to 0% for
practically all the tested concentrations, being significantly lower
than the control values. Man, Fru and GlcNAc also decreased the
RI%. However, this decrease seems to be not as pronounced as
that produced by Glc, with values at 800 mM being around 20%.
The results from the experiments with Gal and GalNAc appear to
be different to those with the other sugars, with no clear trend
observed. Table 1 shows that significant differences compared to
the control values were observed only for 800 mM of Gal or
GalNAc. At this concentration, the RI% values were 58.62 for GalFrontiers in Immunology | www.frontiersin.org 9and 68.45 for GalNAc, i.e., far from 0% and far from the values
obtained with the other sugars at 800 mM. Thus, Glc showed the
largest effect on the interaction between the NS-IgMs and CA,
while Fru, Man and GlcNAc had an intermediate effect, and Gal
and GalNAc had a minor effect. This indicates that there are
some differences in the way in which MS-IgMs and NS-IgMs
interact with CA, in terms of immunoreactivity. However,
generally, the interaction between IgMs and CA seems to
involve carbohydrates, suggesting that the NEs have a
carbohydrate nature.
Digestion Studies
As explained before, to exclude the possible peptidic composition
of the NEs recognized by the IgMs, we checked the IgM stainingFIGURE 4 | Representative images of hippocampal sections stained with MS-IgMs and Hoechst (blue) obtained in the second series (S2). Each row corresponds to
a preadsorption study performed with the indicated carbohydrate. Sugar concentrations are indicated above. As observed in Figure S3, the staining of CA becomes
weaker with increasing sugar concentrations and even disappears. Scale bar: 100 mm.June 2021 | Volume 12 | Article 618193
Riba et al. Neoepitopes in Brain Corpora Amylaceaof CA obtained from the CSF after their digestion with the
peptidic enzyme pepsin. Staining with AF555 NHS ester probe,
a-p62 antibody and fluorescein-labeled ConA were used as
controls. After the digestion with pepsin, the AF555 NHS ester
and a-p62 staining should not appear if the proteins have been
digested, but the staining with ConA should not be affected, as
ConA binds to carbohydrate structures.
First of all, we performed single staining of CA with NHS
ester probe, a-p62, ConA and NS-IgM (Figure 8A). For each
product, we used matching aliquots, one of them digested with
pepsin and the other simply diluted in PBS. As expected, CA
were stained with the NHS ester probe in the absence of pepsin
digestion, but not when CA have been previously digested with
pepsin, indicating that the digestion with pepsin, eliminated all
the peptidic components of the CA. Accordingly, CA were
stained with the a-p62 in absence of pepsin digestion, but not
when CA have been previously digested. Staining with ConA was
not affected by the pepsin digestion, indicating that the glucidic
structure recognized by ConA was not affected by the peptidic
enzyme. Finally, staining with NS-IgMs occurred with and
without the pepsin digestion, indicating that the targets of the
IgMs were not affected by this digestion and, thus, they do not
have a peptidic nature.
Two double staining procedures were performed, using ConA
and the a-p62 antibody in one case and NS-IgMs and a-p62
antibodies in the other. In the first case, CA were stained with
both ConA and the a-p62 antibody in the absence of the pepsin
digestion, while after the pepsin digestion the ConA staining can
be observed but not that of p62 (Figure 8B). Similarly, pepsin
digestion led to the disappearance of the a-p62 antibody
staining, but did not affect NS-IgM staining in the double
immunostaining with the a-p62 antibody and NS-IgMs
(Figure 8C), indicating that the NEs recognized by the IgMs
are not of a peptidic nature.DISCUSSION
In previous studies, we had determined that CA in the human
brain exhibit NEs that are recognized by plasma IgMs, which are
in fact natural IgMs (10). The present study aimed to clarify the
nature of these NEs, and we adapted standard techniques to
this purpose.
Since the preadsorption of ConA with specific sugars
interferes with the interaction between ConA and CA, and
given that the sugar preadsorption of antibodies directed
against proteins do not disrupt their interaction with CA, we
used this strategy to study the interaction between IgMs and CA.
We observed that the preadsorption of IgMs with specific
carbohydrates had inhibitory effects. On the other hand, we
found that the digestion of CA with pepsin, that eliminates their
proteinaceous components, removes the staining with NHS ester
probe and a-p62 while that of ConA is maintained, indicating
that the sugar target of ConA has not been altered. We also
observed that the pepsin digestion has no effect on IgM staining,
thus excluding the peptidic nature of the NEs. Altogether, allFrontiers in Immunology | www.frontiersin.org 10these results strongly support that the NEs contained in CA have
a carbohydrate nature.
Glycans have multiple complex functions, including acting as
“eat-me” signals to induce phagocytosis by macrophages or
dendritic cells, either directly or indirectly, for example, via
opsonization with natural IgMs (46, 50). Recently, Xia and
Gildersleeve, analyzing a-glycan IgM repertoires in newborn
human cord blood, reported that many a-glycan antibodies
present in human sera belong to the IgM class and are natural
antibodies (49), with natural IgMs estimated to constitute between
80% and 90% of natural antibodies (46). Membrane-derived
epitopes are among the NEs recognized by these antibodies (56).
Such epitopes include carbohydrate determinants generally
anchored to intracellular membranes that act as “eat-me” signals
when exposed to the outside of the cell, for example, when
apoptosis occurs or in cell debris (56). In fact, under
physiological conditions, there are multiple elements inside cells
that can act as “eat-me” signals when externalized. This is an
energy-saving process for the body because in the case of
functional or structural alterations, it is not necessary to
generate these signals de novo, but it is enough to relocate them
to the outside of the cell (56). For all these reasons, given that CA
accumulate different residual elements and that they can act as
waste containers that are part of the brain cleaning system, it
would not be surprising that different species of NEs with a
carbohydrate nature occur in CA. Some of these could
participate in the phagocytosis of CA by macrophages, a process
that has been observed in nerve tissue samples from cases of
neuromyelitis optica (17) and in in vitro studies (24).
In the present study, we used two different pools of IgMs
(NS-IgMs and MS-IgMs). The binding of the NS-IgMs to CA was
affected to varying levels by the different sugars, withGlc having the
largest effect, reducing the RI% to 0% at a concentration of 50 mM.
Gal andGalNAchad the smallest effects, producinga slightdecrease
in staining only at the highest concentration tested (800mM),when
the RI% value was around 60%. This suggests that the equatorial
arrangement of the hydroxyl group at C-4 in themonosaccharide is
critical for its interaction with IgMs. Moreover, the equatorial or
axial arrangement of the hydroxyl group at C-2 might also have
some importance. This is illustrated by the lower inhibition exerted
by Man compared to Glc and also in the comparison of the
inhibitions produced by Glc and GlcNAc, in which the hydroxyl
groupatC-2 is substitutedwithNAc.The effects of the changes atC-
2, however, are not as strong as those at C-4.
The four monosaccharides tested interfered with the binding
of the MS-IgMs to CA, with no significant differences observed
among the sugars. This different behavior of MS-IgMs compared
to NS-IgMs could be due to the fact that the former come from
an extract of myeloma serum and, therefore, this pool of IgMs is
restricted and possibly altered with respect to the pool of IgMs
found in normal serum (NS-IgMs). However, it should be noted
that in both cases, the interaction between the IgMs and CA was
inhibited by the sugars, further supporting the carbohydrate
nature of the NEs of CA that were recognized by these IgMs.
We do not know whether there is only one type of NE in CA or
whether there is a collection of different NEs. In any case, theJune 2021 | Volume 12 | Article 618193
Riba et al. Neoepitopes in Brain Corpora AmylaceaFIGURE 5 | Representative images of hippocampal sections stained with NS-IgMs and Hoechst (blue) obtained in the first series (S1). Each row corresponds to a
preadsorption study performed with the indicated carbohydrate. Sugar concentrations are indicated above. Scale bar: 100 mm.Frontiers in Immunology | www.frontiersin.org June 2021 | Volume 12 | Article 61819311
Riba et al. Neoepitopes in Brain Corpora AmylaceaFIGURE 6 | Representative images of hippocampal sections stained with NS-IgMs and Hoechst (blue) obtained in the second series (S2). Each row corresponds to
a preadsorption study performed with the indicated carbohydrate. Sugar concentrations are indicated above. Scale bar: 100 mm.Frontiers in Immunology | www.frontiersin.org June 2021 | Volume 12 | Article 61819312
Riba et al. Neoepitopes in Brain Corpora Amylaceabinding of the IgMs to these NEs of CA can be completely
blocked by certain monosaccharides.
The present work indicates that the binding between certain
human IgMs and certain antigens or epitopes present in human
structures can be inhibited in vitro by certain monosaccharides,
especially glucose. Therefore, we wondered whether these
inhibitions also occur in vivo. In human sera, the IgM
concentration in early adulthood is 1.46 ± 0.12 mg/ml (57),
while the normal plasma glucose two hours after eating is about
7.8 mM (58). In our study, the NS-IgM concentration was 0.044Frontiers in Immunology | www.frontiersin.org 13mg/ml, while the lowest glucose concentration used to preadsorb
the NS-IgM was 50 mM or, more precisely, 48.1 mM if we take
into account the addition of the antibody during the antibody
dilution. Therefore, the Glc/IgM ratio in our experimental
conditions was about 205 times higher than that in
physiological conditions. In any case, taking into account that
in our experimental conditions the RI% decreases to about 0% at
48.1 mM of Glc concentration, we may consider that
physiological levels of Glc could also induce some inhibitory
effects on IgM. In this sense, it must be pointed that short-termA B
C D
E F
FIGURE 7 | Graphical view of the RI% mean values (± s.e.m.) of fluorescence resulting from the staining of CA with ConA, a-p62 antibody, MS‐IgM or NS-IgM that
have been preadsorbed with the indicated sugars at the indicated concentrations. S1 and S2 correspond to data from the different series. The data and significant
differences are detailed in Table 1. Note in (A) the decrease produced by Glc, Fru, Man and GlcNAc, but not by Gal and GalNAc, in the ConA staining of CA. In (B)
(corresponding to a-p62 antibody staining), note that the lines do not show the downward trend in relation to the sugar concentration for any of the four sugars
tested. On the contrary, (C, D) show that staining with MS‐IgMs (S1 and S2) is affected by the presence of the sugars. Staining with NS-IgMs (E, F) is also affected
by the presence of the sugars. See text for details.June 2021 | Volume 12 | Article 618193
Riba et al. Neoepitopes in Brain Corpora Amylaceahyperglycemia influence the innate immune system (59).
Furthermore, diabetes mellitus increases susceptibility to viral,
bacterial and fungal infections through modulating the immune
system (59–61). Although different mechanisms have been
described to explain this, including the activation of protein
kinase C and the glycosylation of some proteins (59), the possible
inhibition of IgM reactivity by glucose or other sugars has not
been investigated to date. Thus, the present work introduces a
new focus of interest.
In summary, the present work indicates that the NEs in CA
have a carbohydrate nature. Furthermore, it indicates that the
natural IgMs that recognize these NEs can be blocked in vitro byFrontiers in Immunology | www.frontiersin.org 14preadsorption with different sugars, particularly glucose. Finally,
our findings reveal the need to study the effects that glycemia
produce in vivo on the reactivity of natural IgMs and,
consequently, on natural immunity.DATA AVAILABILITY STATEMENT
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